05.11.2018 | short review
The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018Einloggen, um Zugang zu erhalten
At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.